Content about Merck

October 9, 2013

Flu is at the top of the list of diseases older adults plan to ask about, according to results from a new Harris Interactive consumer awareness survey, sponsored by Merck. Most of the more than 600 surveyed adults age 60 years and older are at least somewhat likely to ask their healthcare professional about preventing the flu this year, and are significantly more likely to ask about this than prevention of such other potentially serious diseases as shingles.

WHITEHOUSE STATION, N.J. — Flu is at the top of the list of diseases older adults plan to ask about, according to results from a new Harris Interactive consumer awareness survey, sponsored by Merck. Most of the more than 600 surveyed adults age 60 years and older are at least somewhat likely to ask their healthcare professional about preventing the flu this year, and are significantly more likely to ask about this than prevention of such other potentially serious diseases as shingles.

September 26, 2013

Merck Consumer Care announced that Oxytrol for Women is now on shelf for the more than 20 million women suffering from overactive bladder.

WHITEHOUSE STATION, N.J. — Merck Consumer Care on Wednesday announced that Oxytrol for Women is now on shelf for the more than 20 million women suffering from overactive bladder. Oxytrol for Women is a thin, flexible patch that is discreetly applied to the abdomen, hip or buttock once every four days for the relief of overactive bladder in women. It is the first and only over-the-counter option that treats the OAB symptoms — urinary incontinence, urgency and frequency — which can take a physical and emotional toll on women.

September 19, 2013

A trade group for the generic pharmaceutical industry is hoping the Food and Drug Administration will allow biosimilars to share the same generic names as their branded biologic counterparts, saying that giving biosimilars their own generic names would not enhance safety.

WASHINGTON — A trade group for the generic pharmaceutical industry is hoping the Food and Drug Administration will allow biosimilars to share the same generic names as their branded biologic counterparts, saying that giving biosimilars their own generic names would not enhance safety.

September 10, 2013

European regulators have approved the European Union's first biosimilar monoclonal antibody. The new product, made by U.S.-based Hospira, comes seven years after the approval of Europe's first biosimilar.

LEAMINGTON SPA, United Kingdom — European regulators have approved the European Union's first biosimilar monoclonal antibody. The new product, made by U.S.-based Hospira, comes seven years after the approval of Europe's first biosimilar.

Hospira announced Tuesday the European Medicines Agency's approval of Inflectra (infliximab) for the treatment of autoimmune disorders like rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.

September 10, 2013

Drug maker Depomed has expanded the geographic scope of a license agreement it has with Merck for diabetes drugs, the company said.

NEWARK, Calif. — Drug maker Depomed has expanded the geographic scope of a license agreement it has with Merck for diabetes drugs, the company said.

The licensing agreement, which the two companies entered in July 2009, gives Merck a non-exclusive license and other rights to certain Depomed patents for extended-release metformin, while Depomed will receive "modest" royalties on net product sales of the drug Janumet XR (sitagliptin; metformin hydrochloride) in countries in which the licensed patents cover the product.

September 10, 2013

Segmenting foot care by calling out products specifically targeting women is still a viable strategy for a category presently climbing at a 2.8% clip toward $672.7 million in device sales for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI.

Segmenting foot care by calling out products specifically targeting women is still a viable strategy for a category presently climbing at a 2.8% clip toward $672.7 million in device sales for the 52 weeks ended July 14 across total U.S. multi-outlets, according to IRI.

August 8, 2013

The big news in incontinence is Oxytrol, which doesn't reach store shelves until September. It's a switched product coming from Merck Consumer Care that brings an entirely new indication to the over-the-counter space — overactive bladder in women.

The big news in incontinence is Oxytrol, which doesn't reach store shelves until September. It's a switched product coming from Merck Consumer Care that brings an entirely new indication to the over-the-counter space — overactive bladder in women.

Some analysts are hesitant to suggest a new OTC category will translate into blockbuster-style sales. However, overactive bladder is a lot like smoking cessation or weight loss in the sense that women don't necessarily discuss these symptoms with their doctors, according to the National Association for Continence.

July 1, 2013

The Food and Drug Administration has declined to approve a sleeping pill made by Merck & Co., citing issues with dosage.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has declined to approve a sleeping pill made by Merck & Co., citing issues with dosage.

The drug maker said Monday that it received a complete response letter from the FDA concerning the drug suvorexant, for which it is seeking regulatory approval. A complete response letter means that the agency has finished reviewing its approval application, but questions remain that preclude final approval.

June 24, 2013

Generic drug makers cannot be held liable if patients suffer harmful side effects after taking their drugs, the Supreme Court has ruled in a 5-4 decision.

WASHINGTON — Generic drug makers cannot be held liable if patients suffer harmful side effects after taking their drugs, the Supreme Court has ruled in a 5-4 decision.

June 4, 2013

AmeriCares on Monday presented its annual Power of Partnership Award to Merck in recognition of the company’s commitment to helping disaster survivors and improving health in the developing world.

STAMFORD, Conn. — AmeriCares on Monday presented its annual Power of Partnership Award to Merck in recognition of the company’s commitment to helping disaster survivors and improving health in the developing world. Merck is one of AmeriCares most committed donors, providing both products and financial support for the global health and disaster relief organization’s aid programs, the organization stated. 

May 30, 2013

This summer, the Supreme Court will decide on a case that could determine whether generic drug makers can be held liable when patients suffer harmful side effects from taking their drugs.

This summer, the Supreme Court will decide on a case that could determine whether generic drug makers can be held liable when patients suffer harmful side effects from taking their drugs.

May 30, 2013

While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.

While the passage of the Patient Protection and Affordable Care Act of 2010 was a milestone in a number of respects, it also was one of the biggest moments in the history of the generic drug industry since the 1984 passage of the Hatch-Waxman Act, which created an abbreviated regulatory approval pathway for generic pharmaceutical drugs.

May 16, 2013

Merck Consumer Care, the makers of Coppertone, launched today the "Making the Sunscreen Grade" program to equip parents with tools to help their children develop lifelong sun habits.

WHITEHOUSE STATION, N.J. — Merck Consumer Care, the makers of Coppertone, launched today the "Making the Sunscreen Grade" program to equip parents with tools to help their children develop lifelong sun habits, including those that protect them from the sun during the school day.

May 8, 2013

Drug maker Merck is seeking regulatory approval for an experimental tablet placed under the tongue that could be used to treat ragweed allergies.

WHITEHOUSE STATION, N.J. — Drug maker Merck is seeking regulatory approval for an experimental tablet placed under the tongue that could be used to treat ragweed allergies.

Merck said the Food and Drug Administration accepted a regulatory application for its ragweed pollen sublingual allergy immunotherapy tablet. Ragweed, also known as Ambrosia artemisiifolia, is a major cause of seasonal allergies in the United States. Merck also submitted an application for a similar drug, for Timothy grass pollen allergies, in March.

May 6, 2013

The Food and Drug Administration has approved a new drug made by Merck for treating high cholesterol, the drug maker said.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has approved a new drug made by Merck for treating high cholesterol, the drug maker said.

Merck announced the approval of Liptruzet (ezetimibe and atorvastatin). The drug combines two preexisting cholesterol drugs: ezetimibe, which Merck markets under the brand name Zetia, and atorvastatin, which Pfizer markets under the name Lipitor. Both drugs are available as generics, but because Liptruzet is a novel combination of them, it required FDA approval as a new drug.

March 19, 2013

The question of whether a generic drug company can be held liable for harmful side effects from its medicines goes before the Supreme Court Tuesday in a case involving a New Hampshire woman who sustained several injuries after taking a generic pain drug.

WASHINGTON — The question of whether a generic drug company can be held liable for harmful side effects from its medicines goes before the Supreme Court Tuesday in a case involving a New Hampshire woman who sustained several injuries after taking a generic pain drug.

March 14, 2013

The Consumer Healthcare Products Association officially elected James Mackey, SVP U.S. region head for Merck Consumer Care, as the association's chairman.

NAPLES, Fla. — The Consumer Healthcare Products Association on Wednesday officially elected James Mackey, SVP U.S. region head for Merck Consumer Care, as the association's chairman. Paul Sturman, president and general manager Pfizer Consumer Healthcare, will serve as immediate past chairman. 

March 8, 2013

Drug maker Merck has hired celebrity chef and cookbook author Leticia Moreinos Schwartz as a spokeswoman to reach out to Hispanics living with Type 2 diabetes, the drug maker said.

WHITEHOUSE STATION, N.J. — Drug maker Merck has hired celebrity chef and cookbook author Leticia Moreinos Schwartz as a spokeswoman to reach out to Hispanics living with Type 2 diabetes, the drug maker said Friday.

February 26, 2013

Bausch + Lomb named Robert Bertolini as president and CFO effective immediately.

ROCHESTER, N.Y. — Bausch + Lomb on Tuesday named Robert Bertolini as president and CFO effective immediately. In this capacity, he will oversee the company's finance, information technology and global quality and operations functions. Bertolini, who assumes CFO responsibilities from Brian Harris, will report to Bausch + Lomb CEO Brent Saunders.  

February 8, 2013

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately.

With growth in traditional pharmaceuticals expected to slow down significantly, a growing number of drug makers — branded and generic alike — see specialty drugs as their main sources of revenue for the foreseeable future. At the same time, those drug makers not invested in specialty may be looking for growth opportunities in consumer health.

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately

January 25, 2013

Merck on Friday announced the Food and Drug Administration has approved the switch of Oxytrol for Women (oxybutynin transdermal system, 3.9 mg/day) from prescription-only to nonprescription, creating a new category — overactive bladder in women — in the OTC area.

WHITEHOUSE STATION, N.J. — Merck on Friday announced the Food and Drug Administration has approved the switch of Oxytrol for Women (oxybutynin transdermal system, 3.9 mg/day) from prescription-only to nonprescription, creating a new category — overactive bladder in women — in the OTC area. Most notable about this switch is the fact that the FDA approved Oxytrol for Women against the majority opinion of its Nonprescription Drug Advisory Committee, which voted five in favor and six opposed to the switch in November. 

January 4, 2013

The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

NEW YORK — The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

Pfizer and EMD Serono announced the approval of Rebif Rebidose (interferon beta-1a), a single-use auto-injector for self-administering Rebif, used to treat relapsing forms of MS. EMD Serono is the U.S. division of German drug maker Merck KGaA, so-named to avoid confusion with U.S.-based Merck & Co.

January 3, 2013

Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

HYDERABAD, India — Dr. Reddy's Labs has launched a generic drug for treating baldness, the Indian drug maker said.

Dr. Reddy's announced the launch of finasteride tablets in the 1-mg strength, a generic version of Merck's Propecia. As the first company to successfully file for approval of a generic version of the drug, Dr. Reddy's is entitled to 180 days of market exclusivity in which to compete directly with the branded version.

Propecia had sales of about $136 million during the 12-month period that ended in October 2012, according to IMS Health.

January 2, 2013

Mylan announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for rizatriptan benzoate orally disintegrating tablets and rizatriptan benzoate tablets, generic versions of Merck's Maxalt MLT Tablets and Maxalt Tablets.

PITTSBURGH — Mylan announced that its subsidiary, Mylan Pharmaceuticals, has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for rizatriptan benzoate orally disintegrating tablets, 5 mg and 10 mg, and rizatriptan benzoate tablets, 5 mg and 10 mg. These products are the generic versions of Merck's Maxalt MLT® Tablets and Maxalt® Tablets, respectively, and are indicated for the acute treatment of migraine with or without aura in adults.

January 2, 2013

Wall Street on Wednesday celebrated the "fiscal cliff" compromise as stocks across the board were trading up by some 200 basis points. As of noon, the Dow was up 1.7% and Nasdaq 2.3%.

NEW YORK — Wall Street on Wednesday celebrated the "fiscal cliff" compromise as stocks across the board were trading up by some 200 basis points. As of noon, the Dow was up 1.7% and Nasdaq 2.3%.